Abstract
Introduction
The management of subependymal giant cells astrocytomas (SEGAs) has been traditionally represented by surgical treatment through an open craniotomic approach. Though open surgery still represents a major option in the management of this kind of tumors, the introduction of mTOR inhibitors in the clinical practice, technological advances in neuroendoscopy and the more recent use of laser interstitial therapy have significantly enlarged the range of available management opportunities.
Methods
A thorough review of the literature has been performed. Accordingly, current views in open surgical treatment, medical therapy, endoscopic tumor removal and new trends (such as laser interstitial thermal therapy) are discussed.
Results
The risk of significant neurological morbidity (5–50%) complicating open surgery has been for a long time representing a main drawback in the management of SEGAs. More recent series report a significant reduction of morbidity and mortality. The mTOR inhibitors have demonstrated efficacy in both warranting a tumor reduction by up to 60% of the tumor size and helping the control of seizures. However, the reported rate of side effects is as high as 30% and tumor recurrence is a documented occurrence at the time of mTOR inhibitor discontinuation. Endoscopic tumor removal has been more extensively considered an option due to the acquisition of new tools. Limits are still represented by tumor size (< 3 cm) and broad attachment of the tumor to the basal ganglia. Laser interstitial thermal therapy (LITT) is the more recently considered option. Though promising, only short follow-up is available so far, while data on medium- and long-term results of this treatment are completely lacking to date.
Conclusions
Surgical treatment remains a mainstay of the management of SEGAs. The indication for an open craniotomic approach should be balanced with an endoscopic tumor removal or LITT according to patient conditions, presence or not of an active hydrocephalus and extension of the attachment of the tumor to the basal ganglia. The mTOR inhibitors do have a definite role both as primary and as adjuvant treatment, but consistent limitations are represented up to now by a not negligible rate of complications and the uncertainties related to the possibility of tumor recurrence once the medical treatment is discontinued.
Similar content being viewed by others
References
Pascual-Castroviejo I, Pascual-Pascual SI, Velázquez-Fragua R, Viaño J, Carceller F, Hernández-Moneo JL, Gutiérrez-Molina M, Morales C (2010) Subependymal giant cell astrocytoma in tuberous sclerosis complex. A presentation of eight paediatric patients. Neurol Engl Ed 25(5):314–321
Moavero R, Romagnoli G, Graziola F, Curatolo P (2015) Mammalian target of rapamycin inhibitors and life-threatening conditions in tuberous sclerosis complex. Semin Pediatr Neurol 22(4):282–294
Roth J, Roach ES, Bartels U, Jóźwiak S, Koenig MK, Weiner HL, Franz DN, Wang HZ (2013) Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol 49(6):439–444
Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66(8):792–796
Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet Lond Engl 372(9639):657–668
Hahn JS, Bejar R, Gladson CL (1991) Neonatal subependymal giant cell astrocytoma associated with tuberous sclerosis: MRI, CT, and ultrasound correlation. Neurology 41(1):124–128
Ouyang T, Zhang N, Benjamin T, Wang L, Jiao J, Zhao Y, Chen J (2016) Retraction note to: Subependymal giant cell astrocytoma: current concepts, management, and future directions. Childs Nerv Syst 32(4):761–761
Curatolo P (2015) Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 52(3):281–289
Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 68(1):64–80
Jóźwiak S, Mandera M, Młynarski W (2015) Natural history and current treatment options for subependymal giant cell astrocytoma in tuberous sclerosis complex. Semin Pediatr Neurol 22(4):274–281
Katz JS, Milla SS, Wiggins GC, Devinsky O, Weiner HL, Roth J (2012) Intraventricular lesions in tuberous sclerosis complex: a possible association with the caudate nucleus. J Neurosurg Pediatr 9(4):406–413
Dracham CB, Shankar A, Madan R (2018) Radiation induced secondary malignancies: a review article. Radiat Oncol J 36(2):85–94
Kumar S (2012) Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health 9(12):4744–4759
Beaumont TL, Limbrick DD, Smyth MD (2012) Advances in the management of subependymal giant cell astrocytoma. Childs Nerv Syst 28(7):963–968
Fohlen M, Ferrand-Sorbets S, Delalande O, Dorfmüller G (2018) Surgery for subependymal giant cell astrocytomas in children with tuberous sclerosis complex. Childs Nerv Syst 34(8):1511–1519
Giordano F, Moscheo C, Lenge M, Biagiotti R, Mari F, Sardi I, Buccoliero AM, Mongardi L, Aronica E, Guerrini R, Genitori L (2019) Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients. Childs Nerv Syst. 36:951–960. https://doi.org/10.1007/s00381-019-04449-w
Harter DH, Bassani L, Rodgers SD, Roth J, Devinsky O, Carlson C, Wisoff JH, Weiner HL (2014) A management strategy for intraventricular subependymal giant cell astrocytomas in tuberous sclerosis complex. J Neurosurg Pediatr 13(1):21–28
Kotulska K, Borkowska J, Mandera M, Roszkowski M, Jurkiewicz E, Grajkowska W, Bilska M, Jóźwiak S (2014) Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. Childs Nerv Syst 30(12):2037–2042
Amin S, Carter M, Edwards RJ, Pople I, Aquilina K, Merrifield J, Osborne JP, O’Callaghan FJK (2013) The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. Eur J Paediatr Neurol 17(1):36–44
Jiang T, Jia G, Ma Z, Luo S, Zhang Y (2011) The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst 27(1):55–62
de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard J-M, Chiron C, Delalande O (2007) Subependymal giant-cell astrocytomasin pediatric tuberous sclerosis disease. Neurosurgery 60(1):83–90
Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL (2003) Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 19(4):232–243
Di Rocco C, Iannelli A, Marchese E (1995) On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 23(3):115–121
Sinson G, Sutton LN, Yachnis AT, Duhaime A-C, Schut L (1994) Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 20(4):233–239
Jansen AC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, D'Amato L, Beaure d'Augères G, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Kingswood JC (2019) Newly diagnosed and growing subependymal giant cell astrocytoma in adults with tuberous sclerosis complex: results from the international TOSCA study. Front Neurol 10:821
Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group (2013) Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49(4):243–254
Frèrebeau P, Benezech J, Segnarbieux F, Harbi H, Desy A, Marty-Double C (1985) Intraventricular tumors in tuberous sclerosis. Childs Nerv Syst 1(1):45–48
Koenig MK, Butler IR, Northrup H (2008) Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 23:1238–1239. https://doi.org/10.1177/0883073808321764
Kumar R, Singh V (2004) Subependymal giant cell astrocytoma: a report of five cases. Neurosurg Rev. 27:274–280. https://doi.org/10.1007/s10143-004-0339-4
Sun P, Kohrman M, Liu J, Guo A, Rogerio J, Krueger D (2012) Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin 28(4):657–663
Franz DN (2011) Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 11(8):1181–1192
Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671–688
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363(19):1801–1811
Curatolo P, Nabbout R, Lagae L, Aronica E, Ferreira JC, Feucht M, Hertzberg C, Jansen AC, Jansen F, Kotulska K, Moavero R, O'Callaghan F, Papavasiliou A, Tzadok M, Jóźwiak S (2018) Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol 22(5):738–748
Franz D (2013) Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biol Targets Ther 7:211
French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. The Lancet 388(10056):2153–2163
Moavero R, Carai A, Mastronuzzi A, Marciano S, Graziola F, Vigevano F, Curatolo P (2017) Everolimus alleviates obstructive hydrocephalus due to subependymal giant cell astrocytomas. Pediatr Neurol 68:59–63
Hallett L, Foster T, Liu Z, Blieden M, Valentim J (2011) Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review. Curr Med Res Opin 27(8):1571–1583
Tiberio D, Franz DN, Phillips JR (2011) Regression of a cardiac rhabdomyoma in a patient receiving everolimus. PEDIATRICS 127(5):e1335–e1337
Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA (2014) Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr 164(5):1195–1200
Cohen AR (1993) Endoscopic ventricular surgery. Pediatr Neurosurg 19(3):127–134
Jallo GI, Morota N, Abbott R (1996) Introduction of a second working portal for neuroendoscopy. Pediatr Neurosurg 24(2):56–60
Gaab MR, Schroeder HWS (1998) Neuroendoscopic approach to intraventricular lesions. J Neurosurg 88(3):496–505
Esposito F, Di Rocco F, Zada G, Cinalli G, Schroeder HWS, Mallucci C, Cavallo LM, Decq P, Chiaramonte C, Cappabianca P (2013) Intraventricular and skull base neuroendoscopy in 2012: a global survey of usage patterns and the role of intraoperative neuronavigation. World Neurosurg 80(6):709–716
Hidalgo ET, Ali A, Weiner HL, Harter DH (2016) Resection of intraventricular tumors in children by purely endoscopic means. World Neurosurg 87:372–380
Cinalli G, Imperato A, Mirone G, Di Martino G, Nicosia G, Ruggiero C, Aliberti F, Spennato P (2017) Initial experience with endoscopic ultrasonic aspirator in purely neuroendoscopic removal of intraventricular tumors. J Neurosurg Pediatr 19(3):325–332
Mohanty A, Thompson BJ, Patterson J (2013) Initial experience with endoscopic side cutting aspiration system in pure neuroendoscopic excision of large intraventricular tumors. World Neurosurg 80(5):655.e15–655.e21
Oka K, Co Y, Yamamoto M, Kumate S, Tomonaga M (1999) Experience with an ultrasonic aspirator in neuroendoscopy. Min - Minim Invasive Neurosurg 42(01):32–34
Rodgers SD, Bassani L, Weiner HL, Harter DH (2012) Stereotactic endoscopic resection and surgical management of a subependymal giant cell astrocytoma. J Neurosurg Pediatr 9(4):417–420
Cai R, Di X (2010) Combined intra- and extra-endoscopic techniques for aggressive resection of subependymal giant cell astrocytomas. World Neurosurg 73(6):713–718
Engh JA, Lunsford LD, Amin DV, Ochalski PG, Fernandez-Miranda J, Prevedello DM, Kassam AB (2010) Stereotactically guided endoscopic port surgery for intraventricular tumor and colloid cyst resection. Oper Neurosurg 67(3):ons198–ons205
Dadey DYA, Kamath AA, Leuthardt EC, Smyth MD (2016) Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report. Neurosurg Focus 41(4):E9
Tovar-Spinoza Z, Ziechmann R, Zyck S (2018) Single and staged laser interstitial thermal therapy ablation for cortical tubers causing refractory epilepsy in pediatric patients. Neurosurg Focus 45(3):E9
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that are no conflict of interest to disclose.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Frassanito, P., Noya, C. & Tamburrini, G. Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis. Childs Nerv Syst 36, 2527–2536 (2020). https://doi.org/10.1007/s00381-020-04889-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-020-04889-9